BridgeBio Pharma, Inc. Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest
BridgeBio Pharma, Inc. (BBIO) reported Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest of -$155.89 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-08-10
- BridgeBio Pharma, Inc. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$155.89M.
- BridgeBio Pharma, Inc. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$166.57M.
- BridgeBio Pharma, Inc. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$194.63M.
- BridgeBio Pharma, Inc. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$184.94M.
- BridgeBio Pharma, Inc. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for fiscal 2025 was -$732.93M.
- BridgeBio Pharma, Inc. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for fiscal 2024 was -$543.37M.
- BridgeBio Pharma, Inc. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for fiscal 2023 was -$652.89M.
- BridgeBio Pharma, Inc. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for fiscal 2022 was -$484.85M.
| Period end | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 1 month | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$155.89M 10-Q · filed 2026-08-10 | -$322.46M 10-Q · filed 2026-08-10 | -$517.09M derived: sum of 3 quarters · filed 2026-08-10 | -$702.03M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2026-03-31 | -$166.57M 10-Q · filed 2026-05-07 | -$361.20M derived: sum of 2 quarters · filed 2026-05-07 | -$546.14M derived: sum of 3 quarters · filed 2026-05-07 | -$729.89M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-12-31 | -$194.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$379.56M derived: sum of 2 quarters · filed 2026-02-24 | -$563.32M derived: sum of 3 quarters · filed 2026-08-10 | -$732.93M 10-K · filed 2026-02-24 | |
| 2025-09-30 | -$184.94M 10-Q · filed 2025-10-29 | -$368.69M derived: sum of 2 quarters · filed 2026-08-10 | -$538.31M 10-Q · filed 2025-10-29 | -$805.70M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-06-30 | -$183.76M 10-Q · filed 2026-08-10 | -$353.37M 10-Q · filed 2026-08-10 | -$620.76M derived: sum of 3 quarters · filed 2026-08-10 | -$785.00M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-03-31 | -$169.62M 10-Q · filed 2026-05-07 | -$437.00M derived: sum of 2 quarters · filed 2026-05-07 | -$601.25M derived: sum of 3 quarters · filed 2026-05-07 | -$676.80M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | -$267.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$431.63M derived: sum of 2 quarters · filed 2026-02-24 | -$507.18M derived: sum of 3 quarters · filed 2026-02-24 | -$543.37M 10-K · filed 2026-02-24 | |
| 2024-09-30 | -$164.25M 10-Q · filed 2025-10-29 | -$239.79M derived: sum of 2 quarters · filed 2025-10-29 | -$275.98M 10-Q · filed 2025-10-29 | -$446.31M derived: sum of 4 quarters · filed 2026-02-24 | |
| 2024-06-30 | -$75.55M 10-Q · filed 2025-08-05 | -$111.74M 10-Q · filed 2025-08-05 | -$282.07M derived: sum of 3 quarters · filed 2026-02-24 | -$461.59M derived: sum of 4 quarters · filed 2026-02-24 | |
| 2024-03-31 | -$36.19M 10-Q · filed 2025-04-29 | -$206.52M derived: sum of 2 quarters · filed 2026-02-24 | -$386.04M derived: sum of 3 quarters · filed 2026-02-24 | -$546.66M derived: sum of 4 quarters · filed 2026-02-24 | |
| 2023-12-31 | -$170.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$349.85M derived: sum of 2 quarters · filed 2026-02-24 | -$510.48M derived: sum of 3 quarters · filed 2026-02-24 | -$652.89M 10-K · filed 2026-02-24 | |
| 2023-09-30 | -$179.52M 10-Q · filed 2024-11-12 | -$340.14M derived: sum of 2 quarters · filed 2024-11-12 | -$482.56M 10-Q · filed 2024-11-12 | -$623.11M derived: sum of 4 quarters · filed 2025-02-20 | |
| 2023-06-30 | -$160.63M 10-Q · filed 2024-08-01 | -$303.04M 10-Q · filed 2024-08-01 | -$443.59M derived: sum of 3 quarters · filed 2025-02-20 | -$583.71M derived: sum of 4 quarters · filed 2025-02-20 | |
| 2023-03-31 | -$142.42M 10-Q · filed 2024-05-02 | -$282.97M derived: sum of 2 quarters · filed 2025-02-20 | -$423.08M derived: sum of 3 quarters · filed 2025-02-20 | -$425.68M derived: sum of 4 quarters · filed 2025-02-20 | |
| 2022-12-31 | -$140.55M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | -$280.66M derived: sum of 2 quarters · filed 2025-02-20 | -$283.27M derived: sum of 3 quarters · filed 2025-02-20 | -$484.85M 10-K · filed 2025-02-20 | |
| 2022-09-30 | -$140.11M 10-Q · filed 2023-11-02 | -$142.72M derived: sum of 2 quarters · filed 2023-11-02 | -$344.30M 10-Q · filed 2023-11-02 | -$496.73M derived: sum of 4 quarters · filed 2024-02-22 | |
| 2022-06-30 | -$2.60M 10-Q · filed 2023-08-03 | -$204.18M 10-Q · filed 2023-08-03 | -$356.62M derived: sum of 3 quarters · filed 2024-02-22 | -$517.65M derived: sum of 4 quarters · filed 2024-02-22 | |
| 2022-03-31 | -$201.58M 10-Q · filed 2023-05-04 | -$354.01M derived: sum of 2 quarters · filed 2024-02-22 | -$515.05M derived: sum of 3 quarters · filed 2024-02-22 | -$617.03M derived: sum of 4 quarters · filed 2024-02-22 | |
| 2021-12-31 | -$152.43M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$313.47M derived: sum of 2 quarters · filed 2024-02-22 | -$415.45M derived: sum of 3 quarters · filed 2024-02-22 | -$586.78M 10-K · filed 2024-02-22 | |
| 2021-09-30 | -$161.03M 10-Q · filed 2022-11-03 | -$263.01M derived: sum of 2 quarters · filed 2022-11-03 | -$434.35M 10-Q · filed 2022-11-03 | -$569.64M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2021-06-30 | -$101.98M 10-Q · filed 2022-08-04 | -$273.31M 10-Q · filed 2022-08-04 | -$408.61M derived: sum of 3 quarters · filed 2023-02-23 | -$539.17M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2021-03-31 | -$171.33M 10-Q · filed 2022-05-05 | -$306.63M derived: sum of 2 quarters · filed 2023-02-23 | -$437.19M derived: sum of 3 quarters · filed 2023-02-23 | -$573.27M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2020-12-31 | -$135.29M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$265.86M derived: sum of 2 quarters · filed 2023-02-23 | -$401.94M derived: sum of 3 quarters · filed 2023-02-23 | -$505.55M 10-K · filed 2023-02-23 | |
| 2020-09-30 | -$130.56M 10-Q · filed 2021-11-04 | -$266.65M derived: sum of 2 quarters · filed 2021-11-04 | -$370.26M 10-Q · filed 2021-11-04 | -$454.31M derived: sum of 4 quarters · filed 2022-02-25 | |
| 2020-06-30 | -$136.08M 10-Q · filed 2021-08-05 | -$239.69M 10-Q · filed 2021-08-05 | -$323.74M derived: sum of 3 quarters · filed 2022-02-25 | -$384.25M derived: sum of 4 quarters · filed 2022-02-25 | |
| 2020-03-31 | -$103.61M 10-Q · filed 2021-05-06 | -$187.66M derived: sum of 2 quarters · filed 2022-02-25 | -$248.17M derived: sum of 3 quarters · filed 2022-02-25 | -$322.50M derived: sum of 4 quarters · filed 2022-02-25 | |
| 2019-12-31 | -$84.05M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | -$144.56M derived: sum of 2 quarters · filed 2022-02-25 | -$218.90M derived: sum of 3 quarters · filed 2022-02-25 | -$288.33M 10-K · filed 2022-02-25 | |
| 2019-09-30 | -$60.51M 10-Q · filed 2020-11-05 | -$134.85M derived: sum of 2 quarters · filed 2020-11-05 | -$204.28M 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | -$69.00K 10-Q · filed 2019-08-14 | -$74.33M 10-Q · filed 2020-08-11 | -$143.77M 10-Q · filed 2020-08-11 | ||
| 2019-03-31 | -$69.44M 10-Q · filed 2020-05-14 | ||||
| 2018-12-31 | -$169.45M 10-K · filed 2021-02-25 | ||||
| 2017-12-31 | -$43.83M 10-K · filed 2020-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |